Search filters

Filters
Clear All

Phase

  • 1
  • 2
  • 3
  • 1
  • 7
  • 6
  • 7
  • 6
  • 1

Found 7 Lymphoma, B-Cell trials

A listing of Lymphoma, B-Cell medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Retreatment with CTL019/CTL119 in Patients with Late Relapse of B-Cell Lymphomas
18 years - 99 years
All genders
Phase 1
Interventional
The primary objective of this study is to evaluate the safety of retreatment of patients with CTL019/CTL119 therapy who have experienced late relapse of lymphoma.
99 years or below
All genders
Phase 2
Please refer to Protocol Section 2.0. Please refer to Protocol Section 12.0 Please refer to Protocol Section 12.0
 Managed Access Program (MAP) to provide access to CTL019  for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
99 years or below
All genders
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
Learn More
Online study
99 years or below
All genders
Phase 2
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
99 years or below
All genders
Phase 2
The purpose of this study is to determine the safety and tolerability of pembrolizumab in people with lymphoma whose lymphoma relapsed or did not respond after receiving at least one prior treatment for lymphoma. This study will also determine how well patients with lymphoma respond to pembrolizumab.
99 years or below
All genders
Phase 1
The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.